In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

ACVC Biomarker Talks

A project from the ACVC Biomarkers Study Group

Association for Acute CardioVascular Care
Acute Cardiac Care

A series of concise and interactive online events covering the full spectrum of biomarkers.

Each talk will be followed by an editorial article published in the European Heart Journal - Acute CardioVascular Care.



What are the ACVC Biomarker Talks?

Smart student learning using internet and headphonesThis series was designed by course directors Christian Müller and Nicholas Mills, chair and co-chair of the ACVC Study Group on Biomarkers.

 

The talks, in a nutshell:

  • Live and interactive online events covering each topic in the biomarker field;
  • Each talk will be moderated by Christian Mueller and Nicholas Mills, and presented by one expert;
  • Each talk will last for 30 minutes and include a 15-20 minute state-of-the-art presentation and 10-15 minute discussion with the audience;
  • The on-demand video will be available 24 hours after the live event.

 

  Register for the entire series

 

 Upcoming talks

Use of BNP and NT-proBNP in the emergency room (18 May 2022)

Speaker: Lori Daniels

Learning objectives

After watching this webinar, participants will:

  • understand the unmet need without BNP/NT-proBNP – symptoms and signs of HF have insufficient sensitivity and specificity. Therefore, relevant uncertainty regarding the presence of HF remains without BNP/NT-proBNP;
  • know the basic concept of NP pathophysiology – BNP/NT-proBNP are quantitative markers of hemodynamic cardiac stress and, therefore, HF. They quantify the presence and extent of LV systolic dysfunction, LV diastolic dysfunction, valvular dysfunction, and RV dysfunction;
  • appreciate the similarities and small differences between BNP and NT-proBNP;
  • understand the strong scientific bases for the use of BNP/NT-proBNP in the ER – very high and incremental diagnostic accuracy in diagnostic studies, reduced time to decision, and time to discharge in RCTs;
  • know the specific rule-out and rule-in cutoffs to be applied in the ER; and
  • understand obesity as the most important confounder and the concept of how to adjust for obesity.

Discover the talk

Origin and future of cardiac troponin I (21 June 2022)

Speaker: Fred Apple

Learning objectives

After watching this webinar, participants will:

  • have insight into the development of an assay for cardiac troponin I;
  • appreciate the difference between high-sensitivity and contemporary sensitive assays;
  • understand the similarities and differences between cardiac troponin I and T in the lab and in practice; and
  • know how the role of cardiac troponin I testing will evolve in the future.

Discover the talk

Screening the general population – a role for cardiac biomarkers? (13 July 2022)

Speaker: Stefan Blankenberg

Learning objectives

After watching this webinar, participants will:

  • understand the fundamental differences between screening and diagnosis;
  • know the basic concept of cTn and NP pathophysiology cTn as quantitative markers of cardiomyocyte injury, while BNP/NT-proBNP are quantitative markers of hemodynamic cardiac stress and, therefore, HF;
  • appreciate the fact that many cardiac disorders develop during decades in a clinically silent period, with cardiac biomarkers as sensitive tools for relevant pathophysiological cardiac changes;
  • understand the possible therapeutic consequences of screening; and
  • know available data and their limitations.

Discover the talk

How is cardiac troponin released from cardiomyocyte? (21 September 2022)

Speaker: Ola Hammarsten

Learning objectives

After watching this webinar, participants will be able to:

  • understand the evolving concept and several hypotheses on how cTn is released from cardiomyocyte;
  • understand that in most settings cTn release indicates irreversible cardiomyocyte injury and cell death; and
  • identify settings in which cTn release may also indicate reversible injury.

Discover the talk

Cardiac biomarkers in the field of cardio-oncology (19 October 2022)

Speaker: Daniela Cardinale

Learning objectives

After watching this webinar, participants will understand:

  • the value and limitations of using hs-cTnT/1 (and BNP/NT-proBNP) monitoring in patients receiving oncological therapy; and
  • the complementary role of blood biomarkers and cardiac imaging in the assessment of cardiotoxicity.

 

An epitaph for CK-MB (23 November 2022)

Speaker: Alan Jaffe

Learning objectives

After watching this webinar, participants will:

  • understand that CK-MB was the preferred biomarker for detection of cardiomyocyte injury and AMI prior to the development of cTn assays;
  • appreciate the different kinetics of CK-M vs. cTn;
  • know that current hs-cTnT/I assays have much higher sensitivity and diagnostic accuracy vs. CK-MB, obviating the use of CK-MB; and
  • appreciate remaining uncertainties in the early detection re-infarction.

 

Inventor and innovator: cardiac troponin T(21 December 2022)

Speaker: Hugo Katus

Learning objectives

After watching this webinar, participants will:

  • understand the structure and function of the cardiac sarcomere;
  • gain insight into the development of an assay for cardiac troponin T;
  • appreciate the impact of the first studies in patients and how they have shaped the diagnosis of acute coronary syndrome;
  • understand that cardiac troponin T measurements can inform other diagnoses and care pathways; and
  • understand how the clinical role for cardiac troponin T testing is likely to evolve in the future.

 Past talks

Date Episodes Title Presented by
27 April 2022 Episode 8   How to deal with unexpected cardiac troponin results Johannes Mair
30 March 2022 Episode 7   Blood and imaging biomarkers in type 2 myocardial infarction Andrew Chapman
23 February 2022 Episode 6   Future application of POC in the emergency room Richard Body
19 January 2022 Episode 5   How to implement novel diagnostic algorithms in the emergency room Louise Cullen
24 November 2021 Episode 4   Biomarkers in atrial fibrillation Ziad Hijazi
27 October 2021 Episode 3   A new diagnostic marker on the horizon - cMyC Michael Marber
23 June 2021 Episode 2   Rapid diagnostic algorithms for NSTEMI Maria Rubini Gimenez
19 May 2021 Episode 1   CV biomarkers in COVID-19 Torbjørn Omland

 

About the ACVC Study Group on Biomarkers

Background

The ACVC Study Group on Biomarkers was established by Kristian Thygesen (DK) in 2005 with the intention of creating a support group for the Global Task Force for the Definition of Myocardial Infarction (later called Universal Definition of Myocardial Infarction - UDMI).

In addition to supporting the UDMI, this group became successful and independent and now focuses on the proper clinical application of cardiac biomarkers including troponins, natriuretic peptides, and inflammatory and thrombotic markers in acute cardiac care.

Objectives

  • disseminating  knowledge about the proper clinical application of cardiac biomarkers in acute cardiovascular care; 
  • advising on the appropriate application of biomarkers in cardiovascular research;
  • creating recommendations/guidelines for implementation of cardiac biomarkers in acute cardiac care; and
  • being a counselling source for authorities regarding the appropriate clinical use of cardiac biomarkers.